Trial Profile
A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs URC 102 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 06 Mar 2017 Status changed from not yet recruiting to completed.
- 21 Aug 2015 New trial record